PL3390448T3 - Terapia dopęcherzowa raka pęcherza moczowego - Google Patents

Terapia dopęcherzowa raka pęcherza moczowego

Info

Publication number
PL3390448T3
PL3390448T3 PL16819062.7T PL16819062T PL3390448T3 PL 3390448 T3 PL3390448 T3 PL 3390448T3 PL 16819062 T PL16819062 T PL 16819062T PL 3390448 T3 PL3390448 T3 PL 3390448T3
Authority
PL
Poland
Prior art keywords
bladder cancer
intravesical therapy
intravesical
therapy
bladder
Prior art date
Application number
PL16819062.7T
Other languages
English (en)
Inventor
Kjetil Hestdal
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure Asa filed Critical Photocure Asa
Publication of PL3390448T3 publication Critical patent/PL3390448T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16819062.7T 2015-12-17 2016-12-19 Terapia dopęcherzowa raka pęcherza moczowego PL3390448T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522311.8A GB201522311D0 (en) 2015-12-17 2015-12-17 Use
PCT/EP2016/081798 WO2017103280A1 (en) 2015-12-17 2016-12-19 Intravesical therapy for bladder cancer

Publications (1)

Publication Number Publication Date
PL3390448T3 true PL3390448T3 (pl) 2024-09-16

Family

ID=55311161

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16819062.7T PL3390448T3 (pl) 2015-12-17 2016-12-19 Terapia dopęcherzowa raka pęcherza moczowego

Country Status (12)

Country Link
US (2) US20180371101A1 (pl)
EP (1) EP3390448B1 (pl)
JP (1) JP2018538308A (pl)
KR (1) KR102878726B1 (pl)
CN (1) CN108699147B (pl)
AU (1) AU2016372570B2 (pl)
DK (1) DK3390448T3 (pl)
ES (1) ES2981986T3 (pl)
FI (1) FI3390448T3 (pl)
GB (1) GB201522311D0 (pl)
PL (1) PL3390448T3 (pl)
WO (1) WO2017103280A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
PE20190921A1 (es) 2016-12-07 2019-06-26 Agenus Inc Anticuerpos y metodos de su utilizacion
MX2020005692A (es) * 2017-12-01 2020-09-25 Sbi Pharmaceuticals Co Ltd Composicion farmaceutica para mejorar el efecto antitumoral mediante el inhibidor del punto de control inmunitario.
WO2024184417A1 (en) 2023-03-07 2024-09-12 Photocure Asa Therapy for bladder cancer
WO2026052815A1 (en) 2024-09-05 2026-03-12 Photocure Asa Use of hal in a method for predicting bladder cancer immunotherapy response

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU708076B2 (en) 1995-03-10 1999-07-29 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8552154B2 (en) * 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
NZ717213A (en) 2008-12-09 2017-10-27 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2013019906A1 (en) 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
ES2808152T3 (es) 2011-11-28 2021-02-25 Merck Patent Gmbh Anticuerpos anti-PD-L1 y usos de los mismos
KR102129636B1 (ko) 2012-05-31 2020-07-03 제넨테크, 인크. Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
ES2994611T3 (en) * 2015-10-19 2025-01-27 Cg Oncology Inc Methods of treating solid or lymphatic tumors by combination therapy
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use

Also Published As

Publication number Publication date
BR112018012116A2 (en) 2018-12-04
CN108699147A (zh) 2018-10-23
DK3390448T3 (da) 2024-07-22
AU2016372570B2 (en) 2024-01-18
KR20180094988A (ko) 2018-08-24
CN108699147B (zh) 2022-11-01
AU2016372570A1 (en) 2018-07-12
WO2017103280A1 (en) 2017-06-22
ES2981986T3 (es) 2024-10-14
US11066478B2 (en) 2021-07-20
EP3390448A1 (en) 2018-10-24
EP3390448B1 (en) 2024-06-05
US20180371101A1 (en) 2018-12-27
US20190241672A1 (en) 2019-08-08
RU2018124866A3 (pl) 2020-02-26
RU2018124866A (ru) 2020-01-17
WO2017103280A9 (en) 2017-11-09
KR102878726B1 (ko) 2025-10-29
JP2018538308A (ja) 2018-12-27
CA3008548A1 (en) 2017-06-22
FI3390448T3 (fi) 2024-07-10
GB201522311D0 (en) 2016-02-03

Similar Documents

Publication Publication Date Title
IL254705A0 (en) Combination therapy for cancer
IL259017A (en) Cancer cure is intended
ZA201702382B (en) Combination therapy for cancer
IL255060A0 (en) Combined treatment for cancer
EP3180010A4 (en) Combination therapy for treating cancer
EP3258965A4 (en) Combination therapy for cancer treatment
SMT201800303T1 (it) Trattamenti per il cancro
EP3193884A4 (en) Combination therapy for treating cancer
IL249898A0 (en) Combined cancer treatment
ZA201804968B (en) Formulations for treating bladder cancer
ZA201802452B (en) New therapeutic strategies against blood cancer
IL246761A0 (en) Combined cancer treatment
PL3390448T3 (pl) Terapia dopęcherzowa raka pęcherza moczowego
PL3389717T3 (pl) Terapia neoadjuwantowa raka pęcherza moczowego
GB201519734D0 (en) Cancer therapy
GB201522433D0 (en) Cancer treatment
IL259097A (en) Combination therapy for cancer
EP3270898A4 (en) Methods for the treatment of bladder cancer
GB201519375D0 (en) Photodynamic therapy complex
HRP20210383T8 (hr) Kombinirana terapija za rak
GB201511609D0 (en) Cancer therapy
GB201511120D0 (en) Cancer therapy
GB201511121D0 (en) Cancer therapy
GB201514777D0 (en) Cancer Treatments
SG11201801083UA (en) Tumor therapeutic agent